RTTNews — Larimar Therapeutics, Inc. (LRMR) will host an investor event on Monday, June 29, 2026, at 7:45 a.m. ET to provide updates on its Nomlabofusp program for Friedreich’s ataxia.
Friedreich’s ataxia is a progressive, inherited neurodegenerative disorder that impairs coordination, mobility, and overall quality of life. Larimar’s lead compound, Nomlabofusp, is being developed as a potential therapy for both adults and children with the disease.
During the webcast, the company will share a regulatory update and data from the ongoing Phase 2 long‑term open‑label study of Nomlabofusp. Larimar also plans to leverage its intracellular delivery platform to design fusion proteins targeting other rare diseases characterized by deficiencies in intracellular bioactive compounds.
LRMR has traded between $2.71 and $6.42 over the past year. The stock closed Friday at $3.66, up 4.57 %. In after‑hours trading, the stock is at $4.00, up 9.29 %.
Also Read
- Uzbekistan’s Record IPO Redirects Focus Toward Expanding Capital Markets
- ‘Supergirl’ Projected to Earn $40 Million in Opening Weekend, Significantly Underperforming Pre‑Release Estimates
- Pakistan’s PM Warns of India’s Growing Covert Operations Targeting Regional Stability
- Historical Echoes: What Rome and Persia Teach About US-Iran Diplomacy